Ocugen soared over 20% in morning trading because of WHO’s meeting on its partner’s COVID-19 shot

Tiger Newspress2021-10-26

Ocugen soared over 20% in morning trading because of WHO’s meeting on its partner’s COVID-19 shot.WHO will make a decision on the vaccine developed by Bharat Biotech based on the recommendations of the Technical Advisory Group today.

“WHO has been working closely with Bharat Biotech to complete the dossier. The technical advisory group will meet on Oct 26th to consider EUL for Covaxin,”WHO Chief Scientist Soumya Swaminathan said on Twitter recently.

Ocugen cooperated with Bharat Biotech for the commercialization of Covaxin in the United States and Canada.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
16